https://commons.ufh.ac.za/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://commons.ufh.ac.za/vital/access/manager/Repository/vital:26602 Thu 13 May 2021 06:31:38 SAST ]]> https://commons.ufh.ac.za/vital/access/manager/Repository/vital:26600 Thu 13 May 2021 02:49:04 SAST ]]> https://commons.ufh.ac.za/vital/access/manager/Repository/vital:26601 5% w/v led to a reduction in DLC and EE and an increase in PS with minimal impact on the ZP. Stability studies conducted at 25°C/65% RH and 40°C/75% RH for up to 30 days following manufacture revealed that batch SLM 15 manufactured using 10% w/v Labrafil® M2130 CS, 5% w/v KTZ and a combination of 4% w/v Pluronic® F-68, 2% w/v Tween 80 and 1% w/v sodium cholate produced the most stable dosage form when stored at 25°C/65% RH for up to 30 days. However, storage at 40°C/75% RH resulted in instability of the formulation. An aqueous dispersion of KTZ-loaded SLM has been developed and assessed and may offer an alternative to extemporaneous preparations used for KTZ therapy in paediatric and immuno-compromised patients.]]> Thu 13 May 2021 01:07:54 SAST ]]>